Skip to content

Effects of different risk factors on vascular aging

Effects of different risk factors on vascular aging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17013247
Enrollment
Unknown
Registered
2017-11-05
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular aging

Interventions

Five age groups:no

Sponsors

Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.;Inclusion criteria: Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.;Inclusion criteria: Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.;Inclusion criteria: Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.;Inclusion criteria: Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.

Exclusion criteria

Exclusion criteria: Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent; Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months; Patients treated with estrogens, testosterone, or growth hormone.;Exclusion criteria: Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent; Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months; Patients treated with estrogens, testosterone, or growth hormone.;Exclusion criteria: Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent; Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months; Patients treated with estrogens, testosterone, or growth hormone.;Exclusion criteria: Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent; Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months; Patients treated with estrogens, testosterone, or growth hormone.;Exclusion criteria: Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent; Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months; Patients treated with estrogens, testosterone, or growth hormone.

Design outcomes

Primary

MeasureTime frame
Cardio-ankle vascular index;

Secondary

MeasureTime frame
Brachial-ankle pulse wave velocity;Ankle-brachial inde;Central augmentation index;Carotid Intima Media Thickness;Evaluation of retinal vessels;

Countries

China

Contacts

Public ContactGuoxiang Fu;Guoxiang Fu;Guoxiang Fu;Guoxiang Fu;Guoxiang Fu ;;;;

Shanghai Jiao Tong University Affiliated Sixth People's Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital

fuguoxiang888@163.com;fuguoxiang888@163.com;fuguoxiang888@163.com;fuguoxiang888@163.com;fuguoxiang888@163.com+86 18930172740;+86 18930172740;+86 18930172740;+86 18930172740;+86 18930172740

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026